Buscar | SocioMint

Surbhi Verma agregó una foto Health
2026-07-10 10:32:21 -

MEK Inhibitors Market: How Is Neurofibromatosis Type 1 Approval Creating a New Rare-Disease Revenue Stream?
MEK inhibitors targeting neurofibromatosis type 1-associated plexiform neurofibromas — the oral allosteric MEK1/2 inhibitors selumetinib (Koselugo, AstraZeneca) and mirdametinib (Gomekli, SpringWorks Therapeutics) approved for pediatric and adult NF1 patients with symptomatic, inoperable tumors — represent the fastest-growing indication segment in the MEK inhibitor market, with the...

0 Commentarios 0 Acciones 879 Views 0 Vista previa

Please log in to like, share and comment!
Surbhi Verma agregó una foto Health
2026-07-28 10:00:27 -

Subcutaneous Neurofibroma Market: How Are MEK Inhibitors and Topical Therapies Redefining Management Beyond Surgical Excision?
Subcutaneous neurofibromas — the benign peripheral nerve sheath tumors arising within the dermis and subcutis, often multiple and disfiguring in neurofibromatosis type 1 (NF1) patients — have historically been managed through surgical debulking with high recurrence rates and functional morbidity, but the Subcutaneous Neurofibroma Market is now reflecting a therapeutic paradigm shift...

0 Commentarios 0 Acciones 707 Views 0 Vista previa

Please log in to like, share and comment!

SocioMint https://sociomint.com